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ABSTRAK 
Pengenalan Penilaian peringkat awal tahap keberkesanan rawatan kemoterapi yang 
diberikan kepada pesakit limfoma adalah penting kerana ia membolehkan pesakit yang 
tidak bertindak balas dikenal pasti lebih awal. Imbasan interim Fluorine-18 
Fluorodeoxyglucose (F-18 FDG atau FDG) Positron Emission Tomografi – Komputer 
Tomografi (PET-CT) adalah pengimejan imbasan yang masih di peringkat kajian dari 
segi kegunaannya dalam menilai tahap awal keberkesanan rawatan limfoma. Semasa 
menilai tahap keberkesanan rawatan pada peringkat awal, kewujudan lesi yang 
menunjukkan tahap pengambilan  sederhana (lesi MRU) menimbulkan kesukaran dalam 
menentukan keberkesanan rawatan sama ada ia perlu dikategorikan sebagai rawatan 
yang berkesan atau tidak. Bagi mendapatkan maklumat yang lebih lanjut berkaitan lesi 
MRU, kaedah pengimejan imbasan dwi-masa (DTPI) dan analisis semikuantitatif 
digunakan. Tujuan kajian ini adalah untuk menilai kaedah DTPI yang dibuat ke atas lesi 
MRU semasa peringkat awal rawatan sama ada ianya boleh meramal keberkesanan 
rawatan di akhir sesi kemoterapi. 
Metodologi Satu kajian prospektif telah dijalankan di Jabatan Pengimejan Molekul dan 
Perubatan Nuklear, Hospital Canselor Tuanku Muhriz  bermula daripada April 2014 
sehingga Ogos 2015 melibatkan 28 orang pesakit limfoma dengan 67 lesi MRU. Pesakit 
yang terlibat dikenalpasti semasa menjalani sesi imbasan interim FDG PET-CT. Semasa 
sesi imbasan interim FDG PET-CT, kaedah DTPI telah dilaksanakan ke atas lesi MRU 
dan nilai perubahan pengambilan terpiawai maksimum (SUVmax perubahan), 
perubahan isipadu tumor metabolik (MTV perubahan) serta  indeks penahanan (RI) 
dikira. Selepas pesakit menjalani sesi imbasan interim FDG PET-CT, pesakit akan 
menjalani satu lagi imbasan FDG PET-CT yang dibuat setelah sesi kemoterapi tamat. 
Pada peringkat ini, pesakit akan dibahagikan kepada dua kumpulan iaitu kumpulan 
 xiv 
‘responder’ dan kumpulan ‘non-responder’ mengikut tahap keberkesanan rawatan 
berdasarkan Klasifikasi Lugano. Maklumat yang diperolehi daripada kedua-dua 
imbasan iaitu semasa imbasan interim dan  imbasan pada tamat sesi kemoterapi 
kemudiannya dianalisa.  
Keputusan Imbasan interim PET-CT berjaya meramal keberkesanan rawatan untuk sesi 
akhir imbasan PET-CT dengan ketepatan 95%. SUVmax bagi kumpulan ‘responder’ 
adalah lebih rendah jika dibandingkan dengan kumpulan ‘non-responder’. 
Bagaimanapun hasil analisa data yang diperolehi menunjukkan tiada perbezaan yang 
ketara dari segi analisa statistik di antara median SUVmax perubahan (p=0.422) dan 
median MTV perubahan (p=0.933) bagi lesi MRU dalam kumpulan ‘responder’ dengan 
kumpulan ‘non-responder’. Begitu juga tiada perbezaan yang ketara dari segi analisa 
statistik di antara median indeks penahanan (RI) bagi lesi MRU dalam kumpulan 
‘responder’ dan kumpulan ‘non-responder’ (0.862). Lesi MRU dengan nilaian Deauville 
3 semasa imbasan interim PET-CT memberi kesukaran dalam meramal tahap 
keberkesan rawatan di akhir sesi kemoterapi. 
Kesimpulan  Kaedah DTPI terhadap lesi MRU ketika imbasan interim FDG PET-CT 
tidak memberi manfaat dalam meramal status keberkesanan rawatan di akhir sesi 
kemoterapi. 
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ABSTRACT 
 
 
Introduction Early treatment response assessment in lymphoma is important as it 
allows physicians to identify patients with poor response to treat earlier. Interim 
Fluorine-18 Fluorodeoxyglucose (FDG) Positron Emission Tomography – Computed 
Tomography (PET-CT) scan is currently regarded as an investigational imaging tool in 
evaluating early treatment response in lymphoma as clinical trials evaluating it’s use are 
still on-going. The presence of minimal residual uptake (MRU) lesion in interim PET-
CT scan possess uncertainty in interpreting early treatment response whether MRU 
lesion should be considered as representing poor treatment response. To characterize 
MRU lesions in interim FDG PET-CT scan, dual time point imaging (DTPI) technique 
with semi-quantitative analysis is used. This study is aimed to determine the predictive 
value of DTPI technique in predicting the end chemotherapy response of lymphoma 
patients with MRU lesions identified on interim FDG PET-CT scan.  
Methodology Prospective study was performed at the Department of Molecular 
Imaging and Nuclear Medicine, Hospital Canselor Tuanku Muhriz from April 2014 to 
August 2015 recruiting 28 lymphoma patients with 67 MRU lesions. DTPI technique 
was applied to interim FDG PET-CT scan to characterize MRU lesions by measuring 
their early and delayed maximum standardized uptake values (SUVmax) and calculating 
the SUVmax change, changes in metabolic tumour volume (MTV) as well as the 
retention index (RI). Upon completion of chemotherapy, patients underwent end 
treatment FDG PET-CT scan. Patients were divided into responder and non-responder 
group based on Lugano’s Classification for end treatment response assessment.   
Results Interim PET-CT predicted the end-treatment PET-CT findings with accuracy of 
95%. SUVmax of responders was significantly lower than that of non-responder. 
However, there was no statistical significant difference between the median SUVmax 
 xvi 
change (p= 0.422) and median MTV change (p= 0.930) of MRU lesions in responder 
and non-responder groups.  There is also no statistical significant difference between RI 
in responder and non-responder groups (p = 0.862). MRU lesions with Deauville 3 at 
interim PET-CT were less predictable end-treatment response. 
Conclusion DTPI technique applied during interim PET-CT has no predictive role in 
indicating end chemotherapy response in lymphoma patients with MRU lesions.  
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CHAPTER 1 
 
      INTRODUCTION 
 
1.1 Introduction 
 Positron emission tomography – computed tomography (PET-CT) with 
Fluorine-18 Fluorodeoxyglucose (FDG) has become an essential imaging investigation 
in the management of lymphoma. It is used for disease staging and treatment response 
assessment. In terms of assessing treatment response, PET –CT scan performed during 
treatment (interim PET-CT scan) has the potential to be used to assess chemosensitivity 
of tumour and to predict the treatment outcome (Valls et al., 2016). Information 
obtained from interim PET-CT scan is helpful in guiding clinicians in planning the 
chemotherapy with the aims of achieving a better quality of life by minimizing side 
effects as well as prolonging survival. Interim PET-CT scan is considered at present as 
a research tool. Its use in response adapted-chemotherapy trials in lymphoma are 
currently under evaluation.  
 In order to improve the response assessment interpretation in interim PET-CT 
scan, Deauville criteria was introduced in 2009 (Moghbel et al., 2016) . With the 
introduction of Deauville criteria, a  term called minimal residual uptake (MRU) lesion 
which refer to lesion with Deauville score of 2 to 3 was re-defined. The presence of 
MRU lesions in interim PET-CT scan cause a considerable uncertainty in predicting the 
outcome of chemotherapy as well as early response interpretation. In one study 
involving interim FDG PET-CT scan in NHL patients, early stage NHL patients with 
MRU lesions have different outcome compared to advanced stage NHL (Mikhaeel et 
al., 2005). In response adapted-chemotherapy trials, MRU lesion in interim FDG PET-
CT scan is assigned to a different treatment strategy.  
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 In order to further assess MRU lesions, apart from Deauville criteria which is 
based on visual interpretation of FDG PET-CT scan images, semi-quantitative analysis 
with application of dual-time point imaging (DTPI) technique, could be used. 
Maximum standardised uptake value (SUVmax) is an example of semi-quantative  
analysis in which it offer information on quantitative aspect of FDG uptake. DTPI 
technique in PET-CT scan is often used to study tracer kinetics. It has been used in 
investigation of lymphoma and has significantly improved the specificity and sensitivity 
of PET imaging (Michihiro et al., 2013). DTPI technique has been shown to produce 
higher accuracy rate in diagnosis, staging of malignant lymphoma and also in predicting 
the histological grades of malignancy (Takayoshi et al., 2012).  
 This study is designed to evaluate the significance of MRU lesions in interim 
FDG PET-CT by application of DTPI technique. Semi-quantitative analysis of FDG 
uptake by measuring the maximum standardised uptake value (SUVmax) of the  MRU 
lesions in order to study its kinetic behaviour. Retention index (RI) and metabolic 
tumour volume (MTV) of MRU lesion are also calculated to give added value to the 
analysis. The aim of this study is to look for any association between the change of 
SUVmax value, the change of MTV value and RI of MRU lesions obtained during 
interim FDG PET-CT scan with end of treatment response based on FDG PET-CT scan 
results performed after completion of therapy. 
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     CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 General overview of lymphoma 
 Lymphoma is a type of neoplasm involving the lymphatic system (Swerdlow et 
al., 2016). It is a diverse group of diseases that occurs as the result of a clonal expansion 
of lymphocytes. Each types of lymphoma is a disease with a distinct clinical 
manifestation. This biologic diversity gives rise to prominent differences among the 
lymphomas in terms of clinical presentation, pathological characteristics, epidemiology 
and overall management. 
 Based on the World Health Organisation (WHO) classification of lymphoma 
which was published in 2008, lymphoma is divided into several major groups with each 
groups consists of various types and certain types are further divided into sub-types.  
The WHO classification is based on combination of morphology, immunophenotype, 
genetic features, molecular characteristics and clinical presentation. Among these major 
groups, only Hodgkin’s lymphoma (HL), the abnormal lymphocyte is the Reed-
Sternberg cell. This particular lymphocyte is not found in other groups of lymphoma. 
All other groups of lymphoma are called non-Hodgkin lymphoma (NHL) and there are 
about thirty types of NHL. Lymphoma can also be classified based on the rate of 
growth, areas of presentation and by lymphocyte type (Swerdlow et al., 2016). 
 NHL is more common than HL. According to the National Cancer Registry 
2003 and 2007, lymphoma is the sixth most common cancer among Malaysians. Based 
on gender, lymphoma is the sixth most common cancer in males and the eighth most 
common cancer in females. The cancer incidence per 100,000 population for HL is 0.7 
for male and 0.6 for female, and for NHL is 4.7 and 3.4 in male and female, 
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respectively. Among the NHL, the two commonest types of NHL are diffuse large B-
cell lymphoma (DLBCL) and follicular lymphoma (FL) (Armitage et al., 1998). Of all 
NHL cases, DLBCL make-up of 30-58% cases (Tilly et al., 2015) and FL accounting 
for about 20% of all lymphomas (Luminari et al., 2012).  
 Staging for lymphoma is used to identify disease location and extent, offers 
prognostic information, allows useful comparisons among studies and this will give the 
opportunity to assess disease progression or response to treatment. Both HL and NHL 
were staged based on Ann Arbor classification system (Cheson et al., 2007). The Ann 
Arbor staging system was originally published in 1971. In 1989 the ‘Cotswold 
modifications’  was added subsequently to extend the definitions of stage IV disease, 
and also adding the suffix ‘X’ for description of bulky disease (Cheson et al., 2007). In 
2014, the International Conference on Malignant Lymphomas published guidelines for 
the evaluation, disease staging and treatment response assessment of patients with 
malignant lymphomas. The staging system is known as the Lugano Modification of the 
Ann Arbor staging system (Cheson et al., 2014). 
 Chemotherapy options for HL are based on the stage of HL. In general, the main 
chemotherapy regimes used is a combination of adriamycin, bleomycin, vinblastine and 
dacarbazine (ABVD). Other chemotherapy regime is used in advanced stage HL which 
is combination of bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, 
procarbazine and prednisalone (BEACOPP). Radiotherapy is used after completion of 
chemotherapy in limited and intermediate stage of HL. In general, advanced stage 
HL is commonly treated with chemotherapy alone. Radiotherapy treatment is confined 
to patients having large residual masses after chemotherapy (Eichenauer et al., 2011). 
 Chemotherapy options for NHL groups vary because of its heterogenous nature. 
In DLBCL, the combination chemotherapy with rituximab, cyclophospamide, 
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doxorubicin, vincristine and prednisolone (R-CHOP) is the standard chemotherapy 
regime used (Tilly et al., 2015). In FL, the chemotherapy may include a single agent, for 
example rituximab, or multi-agent chemotherapy, like R-CHOP (Luminari et al., 2012). 
 
2.2 Positron Emission Tomography in staging and end-treatment response in 
lymphoma 
Positron emission tomography (PET) is a three-dimensional, noninvasive 
functional imaging tool that has become an important and essential imaging modality in 
clinical oncology. It was first introduced in the early 1950s for brain imaging. In 2001, 
positron emission tomography/X-ray computed tomography (PET-CT) hybrid imaging 
system became commercially available. This has improved the detection and 
localisation of lesions (International Atomic Energy Agency, 2008). 
Fluorine-18 Fluorodeoxyglucose (FDG), a glucose analog, is the commonest 
PET tracer used in clinical oncology. After injection, FDG is taken up by cells. 
Subsequently it is phosphorylated in the same process as glucose. However, the 
phosphorylated product is not further metabolized. It remains trapped in the cells for 
extended periods of time (Weiss et al., 2012). This process of FDG accumulation is 
detected by PET-CT scan, and provides visualisation of glucose consumption by 
different cells in the body. In cancer cells, there is increased in the number of the 
membrane glucose transporters, known as GLUT-1 and GLUT-3, as well as increased 
in enzyme hexokinase and with overall augmented glucose metabolism, making FDG 
the most suitable tracer for measuring viability of malignant cells.  When the anatomical 
imaging tool CT is combined with PET, the hybrid PET-CT scan will deliver more 
precise images that can discriminate between physiological and pathological FDG 
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uptake. PET-CT  scan is also able to differentiate between necrotic masses and viable 
tumours (Kinahan et al., 2010). 
FDG PET scan is a useful functional imaging tool which has a higher sensitivity 
and specificity than conventional imaging in evaluation of lymphoma (Spaepen et al., 
2001). For example, up to 64% of lymphoma patients are found to have residual or 
remaining lesional abnormalities following chemotherapy treatment as a result from the 
development of tumour fibrosis or necrosis. Conventional imaging alone cannot reliably 
differentiate between these abnormalities with active residual tumour.  
In general, most of malignant lymphomas are FDG-avid, including both 
aggressive and indolent subtypes. Examples include HL, Burkitt lymphoma, mantle cell 
lymphoma, anaplastic large T-cell lymphoma, marginal zone lymphoma (nodal), 
lymphoblastic lymphoma, angioimmunoblastic T-cell lymphoma, plasmacytoma, 
natural killer/T-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma 
and peripheral T-cell lymphoma. A few examples of low FDG avid lymphoma include 
small lymphocytic lymphoma, enteropathy-type T-cell lymphoma, MALT marginal 
zone lymphoma, lymphomatoid papulosis and primary cutaneous anaplastic large T-cell 
lymphoma (Sagie et al., 2010). 
PET-CT scan with FDG has been utilised extensively in managing malignant 
lymphoma. It is a recommended imaging modality in disease staging and chemotherapy 
response assessment in FDG avid lymphoma (Cheson B., 2014). Information obtained 
is used to monitor disease progression and guide clinician in management of the 
disease. Lugano Classification, which was introduced in 2014 as an updated version of 
the 2007 Revised Response Criteria for malignant lymphoma, recommends FDG PET-
CT scan for pretreatment staging assessment and end-treatment response assessment 
after completion of treatment.  
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Based on Lugano Classification, the end-treatment FDG PET-CT scan is 
interpreted using a five-point visual scale known as Deauville criteria, also known as 
the London criteria which was introduced in 2009 (Moghbel et al., 2016). The Deauville 
criteria initially proposed as a guideline in interpretation of findings in treatment 
response assessment in interim FDG PET-CT scan (Barrington et al, 2010). FDG uptake 
in the nodal/lesion is compared visually with two reference sites, the mediastinal blood 
pool and the liver, and score from 1 to 5 is given based on the comparison (Table 2.0).  
 
Table 2.0 Deauville Criteria.  
Deauville Criteria 
Point scale Description 
1 No uptake 
2 Uptake ≤ mediastinum 
3 Uptake > mediastinum ≤ liver 
4 Uptake moderately more than liver 
uptake, at any site 
5 Markedly increased uptake at any site and 
new sites of disease 
Source: Valls, L., et al. (2016). ‘FDG-PET imaging in haematological 
malignancies’, Blood Review, vol.30, no.4, July, pp323. 
 
The Deauville criteria is now recommended as guideline in interpretation of 
treatment response assessment in both interim and end-treatment FDG PET-CT scan. 
Four categories of response have been outlined (Cheson et al,. 2014) as follows: (a) 
complete metabolic response – score of 1, 2 or 3; (b) partial metabolic response – score 
of 4 or 5 with reduced FDG uptake; (c) no metabolic response – score of 4 or 5 without 
significant change in FDG uptake; and (d) progressive metabolic disease – score of 4 or 
5 with increased FDG uptake or with new lesions.  
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2.3 Interim FDG PET-CT scan in lymphoma 
 FDG PET-CT scan has been utilised as a monitoring tool in FDG avid 
lymphoma especially in assessing response to treatment given (Johnson et al., 2015). 
Information obtained could be used to alter the treatment for a better outcome. As 
mentioned earlier, FDG PET-CT scan in FDG avid lymphoma is performed before 
initiation of treatment for staging assessment and at the end of treatment for end 
treatment response assessment (Cheson et al,. 2014).  
Interim FDG PET-CT scan refers to scan that is performed during a schedule 
course of chemotherapy, prior to completion. Interim FDG PET-CT scan, at the time of 
this writing, is still considered as an investigational imaging modality and has not yet 
been implemented in clinical practice (Cheeson et al,. 2014). It has a promising role for 
assessment of chemosensitivity and offers prognostic value in predicting end of 
treatment response (Itti et al., 2009). The key interests of interim PET-CT scan in 
lymphoma are to assess its capability in term of predicting the outcome of treatment and 
in assessing chemotherapy sensitivity with the aim of modifying treatment given. 
Interim FDG PET-CT scan has a potential use in response-adapted therapy, 
whereby treatment could be de-escalated in intensity in the setting of a satisfactory early 
response or escalated if early response is inadequate based on interim FDG PET-CT 
scan findings (Hutching et al,. 2009). Deauville criteria, which was mentioned earlier, is 
used to interpret interim FDG PET-CT scan as recommended by Lugano Classification. 
 
2.4 Minimal residual uptake lesion in interim FDG PET-CT scan 
 In 10% of patients diagnosed with HL, whom undergoing interim FDG PET-CT 
scan, a persistent faint residual FDG uptake often observed in a site with previous bulky 
disease and it is interpreted as minimal residual uptake (MRU). MRU was first defined 
 9 
as a FDG uptake just above background, which was unlikely to represent persisting 
disease (Huching et al., 2005). In order to improve interim FDG PET-CT scan 
interpretation and with the introduction of Deauville criteria, the definition of MRU has 
changed and based on Deauville criteria it is defined as lesion or lymph node with score 
2 or 3 (Barrington et al., 2010).  
 High grade NHL patients with MRU lesion in interim FDG PET scan after two 
to three cycles of chemotherapy were found in a study done by Mikhaeel et al., to have 
a different progression free survival (PFS) and overall survival (OS). In this study, 
which was done before introduction of Deauville criteria, recruited one hundred and 
twenty one patients with high grade NHL and underwent interim FDG PET scan. PET-
negative scan was interpreted as non-visualisation of all abnormal disease-related FDG 
uptake. PET-positive scan was interpreted as presence of persistent FDG uptake sites or 
appearance of new sites of increased FDG uptake, related to lymphoma. MRU was 
defined in this study as a focus of low grade FDG uptake within an area of previously 
noted disease, interpreted by the nuclear medicine physicians as likely due to 
inflammatory process but possibility of small volume disease could not be totally 
excluded. Fifty interim FDG PET scans were considered PET-negative, 19 scans were 
with MRU and 52 scans were PET-positive. Early stage  NHL patients with MRU 
lesion showed PFS and OS similar to PET-negative NHL patients and advanced stage 
NHL with MRU lesion showed PFS and OS similar to PET-positive NHL patients. The 
estimated 5 year PFS from this study was 88.8% for PET negative group, 16.2% for the 
PET positive group and 59.3% for the MRU group (Mikhaeel et al., 2005). Results from 
this study demonstrate that MRU lesions require further assessment as to explain the 
reason behind the findings. 
 10 
 An international study to validate the prognostic role of interim FDG PET-CT 
scan in ABVD-treated, advanced-stage HL, using Deauville criteria and to assess the 
concordance rate among reviewers was carried out involving 260 patients. In this study, 
patients underwent FDG PET-CT scan at baseline and  at interim post 2 cycles of 
ABVD chemotherapy. MRU lesions with Deauville score 2 to 3 were considered as 
negative for presence of disease in interim PET-CT scan. They found the sensitivity, 
specificity and accuracy of interim PET-CT were 73%, 94% and 91%, respectively. 
Negative predictive value and positive predictive value were 0.94 and 0.73, 
respectively. There were only 12 false-negative results (6% of interim FDG PET-
negative patients) in which 7 of these were MRU lesions with Deauville score 3. The 
researchers in this study concluded that Deauville criteria is precise, reproducible and 
reliable to be recommended as standard reporting criterion in clinical practice and for 
clinical trials (Biggi et al., 2013).  
There are several on-going clinical trials that are looking into the response-
adapted chemotherapy in advanced HL utilizing interim PET scan with the aim is to 
reduce chemotherapy side effects by changing the chemotherapy. In these clinical trials, 
the MRU lesion is interpreted as negative for presence of disease and the scan is 
considered negative (Cheson et al., 2014). Based on Lugano classification 
recommendation which was introduce in 2014 for treatment response assessment, the 
interpretation of MRU lesion is often based on the intention of the therapy. For 
example, MRU lesion with Deauville score 3 in interim PET scan is considered as 
negative scan if the intention of subsequent treatment is to escalate chemotherapy. 
However if the intention is to de-escalate chemotherapy, MRU lesion with Deauville 
score 3 is considered as positive scan. This is to prevent under treatment (Cheson et al., 
2014). Study performed by Southwest Oncology Group S0816 in which the researchers 
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escalate therapy from ABVD to dose escalated BEACOPP in stage III-IV HL patients 
with interim PET-positive scan. In this study, interim PET-positive scan was defined as 
scan which has lesion with Deauville score 4 and 5. Patients with interim PET-negative 
scan will continue with ABVD therapy. The results from this study showed response-
adapted therapy based on interim PET scan after two cycles of ABVD seems promising 
with a 2-year PFS of 64% for PET-positive patients, which is much higher than 
expected 2-year PFS of 15% to 30%. However despite these results, there were 58 
patients experiencing treatment failure in the interim PET-negative group, and the 2-
year estimate of PFS for 271 patients with interim PET-negative group was 82% (Press 
et al., 2016).   
 
2.5 Maximum Standardised Uptake Value (SUVmax), Dual Time Point Imaging 
(DTPI) technique and Retention Index (RI) 
 FDG PET-CT scan demonstrates the FDG uptake distribution in the body. 
Certain organs in the body utilised the FDG higher than others. It is important to be  
able to recognised the physiological FDG uptake distribution in the body in order to 
avoid misinterpretation of the scan. As described earlier, once FDG is in the cells, it is 
phosphorylated by enzyme hexokinases. FDG cannot be further processed and is 
trapped intracellularly as FDG-6-phosphate. Thus, FDG accumulates in areas with high 
levels of metabolism and glycolysis, for example at sites of inflammation, active tissue 
repair, sites of hyperactivity and also in cancer cells. In neoplastic cells, these increases 
in glucose demands lead to increase uptake of FDG and increased intracellular 
accumulation of FDG-6-phosphate in neoplastic cells relative to normal cells (Weiss et 
al., 2012). With this differentiation of FDG uptake, the areas of higher FDG uptake is 
visualised on the image and with the knowledge of normal physiological FDG 
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distribution in the body, areas of abnormal FDG uptake can be identified. This is the 
basic principle used behind the FDG PET scan visual analysis (Weiss et al., 2012). 
 Standardised uptake value (SUV) is a semi-quantitative analysis of FDG uptake 
in the body. SUV refers to a ratio of FDG uptake in a region of interest to the FDG 
uptake of the rest of body and it is dimensionless. The basic expression for SUV is  
   SUV  =          r       
          (a’/w)  
 
where r is the radioactivity concentration (kBq/ml) measured by the PET scanner within 
a region of interest, a’ is the decay-corrected amount of injected radiolabeled FDG 
(kBq), and w is the weight of the patient (g). Maximum SUV (SUVmax) refers to 
maximum SUV measured in the region of interest.  
Visual analysis of PET images for treatment response assessment is considered 
adequate and sufficient for a positive or negative decision of overall response (Juweid et 
al., 2007). However, evaluation of therapy response during interim FDG PET-CT scan 
especially in clinical trials, some form of semi-quantitation of FDG uptake may be 
helpful (Lin et al., 2007). SUV is helpful in assessing treatment response by comparing 
its value during baseline, interim and  at end of chemotherapy assessment of FDG PET 
scan (Kinahan et al., 2010).  
 As mentioned earlier, increased FDG uptake in the body is a non-specific 
process. FDG uptake can increase in various disease processes either due to benign 
inflammatory process or due to malignant cells with high metabolism. To differentiate 
between benign and malignant processes that produce increased in FDG uptake, dual 
time point imaging (DTPI) technique has been introduced (Houshmand et al., 2016). 
DTPI is an imaging technique that is used to study tracer kinetics. DTPI refers to scan 
procedure that is performed twice on the same subject at a different time point within 
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the same day. With this technique, SUV of a region of interest can be measured on both 
occasion and comparison can be made (Houshmand et al., 2016).  
DTPI FDG PET-CT scan has been utilised in predicting the histological grades 
of malignancy in lymphoma and the SUVmax on 2-hours delayed scan were 
significantly higher than those on 1-hour early scan for all histological grades of 
malignant lymphoma during initial staging (Takayoshi et al., 2012). DTPI PET scan 
also been used for differentiating the lymph nodes between malignant lymphoma and 
benign lesions in which the malignant lymphoma demonstrates higher SUVmax during 
delayed scan (Michihiro et al., 2013).  
DTPI technique has also been used to study the significant of retention index 
(RI) in various disease entities. Retention index is calculated by using this formula: 
     Retention index = SUVmax delayed – SUVmax early 
                          SUVmax early 
 
 In general, retention index reflects the capability of retaining the FDG. High RI 
reflects the capability of the cells in retaining FDG which may indicate association with 
malignancy. In one study, it was shown that the high RI of FDG correlate with the 
expression of hexokinase type II which it is increased in malignant cells (Higashi et al., 
2002). In another study, it was shown that RI of FDG in undifferentiated breast cancer 
was higher than differentiated breast cancer. From this study, high RI indicates 
aggressive disease (Vicente et al., 2012). 
 The FDG uptake in malignant cells was associated with low glucose-6-
phosphatase enzyme activity, and increased glucose uptake through glucose transporter 
proteins, in particular GLUT-1 and GLUT-3, in these cells. Malignant cells also 
demonstrate longer duration of FDG uptake as compared to benign lesions and normal 
tissues (Kumar et al., 2005). Tumours had average SUVmax increase of 12% between 
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early and delayed scan (Takayoshi et al., 2012). In patients with malignant lymphoma, 
there were increased FDG uptake in lymphoma lesions on delayed scans (Takayoshi et 
al., 2012). These findings demonstrate the usefulness of DTPI PET scan in assessing 
tracer kinetics. Consequently, DTPI technique on FDG PET-CT scan could be used to 
evaluate tracer kinetics of MRU lesions in lymphoma patients during interim treatment 
assessment by measuring the change in SUVmax and RI.  
 
2.6 Metabolic tumour volume (MTV) 
 Metabolic tumour volume (MTV) represents the volume of tumour tissues 
showing avid FDG uptake. It combined the dual characteristics of three dimensional 
volumetric data and the metabolic activity of tumour. MTV has been investigated for it 
use as a prognostic factor in lymphoma and also in various other solid tumours. MTV 
has been shown in one study as an independent predictor of  progression free survival in 
HL (Kanoun et al., 2014). Another study has shown that MTV was a better predictor of 
progression free survival compared with SUVmax reduction in diffuse large B-cell 
lymphoma (Malek et al., 2015). In solid tumours, MTV has been shown to be useful in 
predicting short-term outcome to radiotherapy in pharyngeal cancer (Chung et al., 2009) 
and in other study involving oral cavity squamous cell carcinoma treated with primary 
surgery, MTV was found to be an independent adverse prognostic factor for death and 
disease recurrence (Zhang et al., 2014). 
 The combination of MTV and semi quantitative measurement are useful in 
assessing chemoresponse and in predicting the outcome.  The fact that there are 
multiple prognostic factors which influencing the chemotherapy response and outcome 
in lymphoma, the combination of these prognostic factors will further increase the 
accuracy of treatment response prediction. Currently the use of MTV in lymphoma 
chemotherapy response is being evaluated and is not yet included of its application in 
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the latest guidelines (Cheson et al., 2014). In this study, to assist in evaluating the tracer 
kinetics of MRU lesions, the MTV changes of MRU lesions during interim PET-CT 
will be assess using DTPI as a secondary parameter whether it can differentiate between 
responder and non-responder in order to predict the end chemotherapy response. 
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CHAPTER 3 
 
OBJECTIVES AND HYPOTHESES 
 
3.1 Justification of the study 
 
 Interim FDG PET-CT scan in lymphoma is currently considered as an 
investigational tool. Information gathered from interim FDG PET-CT for early 
treatment response evaluation  has the potential to guide physicians in response adaptive 
chemotherapy. However the presence of minimal residual uptake (MRU) lesion during 
interim PET-CT has created uncertainty in the treatment response assessment whether 
this finding should be considered as a poor response (positive PET) or a good response 
(negative PET) to chemotherapy. Since introduction of Lugano’s classification in 2014 
with recommendation of Deauville criteria to be used as guidelines in image 
interpretation of response assessment in interim and end treatment FDG PET-CT, MRU 
lesion with Deauville score 2 or 3 has been considered as a negative finding which 
translates as a good chemotherapy response (Cheson et al., 2014).  At present, various 
clinical trials in response adaptive chemotherapy involving interim FDG PET-CT 
adopting Lugano’s classification are on-going and results are being validated. Further 
study is required to assess MRU lesions characteristics particularly its kinetics behavior 
in interim FDG PET-CT by application of DTPI technique and semi-quantitative 
analysis.  
 
3.2 Benefits of the study 
 
 1. Early identification of patients with poor response to chemotherapy, allowing 
a change in chemotherapy planning. 
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 2. Benefit to patients in term of reducing chemotherapy side effects associated 
with ineffective treatment.  
 3. Reducing patient’s anxiety associated with uncertainty in the treatment 
outcome.  
 
3.3 General objective 
 
 To evaluate the predictive value of dual time point imaging (DTPI) of minimal 
residual uptake (MRU) lesion in interim FDG PET-CT scan in predicting the end post 
chemotherapy response in lymphoma patients. 
 
3.4 Specific objectives 
 
 1. To compare the median of SUVmax  changes and median MTV changes 
between responder and non-responder groups. 
 2. To compare the median SUVmax changes between 4 groups based on revised 
response criteria. 
 3. To evaluate any association between demographic factors and end of 
chemotherapy response. 
 
 
3.5 Research hypothesis 
 
 Increased in SUVmax change of MRU lesion during interim PET-CT 
assessment is associated with poor response at the end of chemotherapy. 
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3.6 Null hypothesis 
 Increased in SUVmax change of MRU lesion during interim PET-CT 
assessment does not associated with poor response at the end of chemotherapy. 
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3.7 Research framework 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lymphoma patient referred for interim 
PET-CT 
Early PET-CT scan, 1 hour post FDG injection 
Image review : Deauville criteria, MRU SUVmax & MTV(early scan) 
Inclusion criteria: + ECOG  score 0-3 + Presence of MRU lesion + Undergoing first line chemo + Age 18-75 years old 
Exclusion criteria: + no MRU lesion     + ECOG score 4 + relapsed lymphoma + previous history of radiotherapy for lymphoma 
Delayed PET-CT scan, 2 hours post FDG injection No further scan, patient excluded from study 
Image review :  MRU SUVmax & MTV(delayed scan), retention index, % MRU SUVmax changes 
Patient continue remaining chemo as scheduled 
PET-CT (end of chemotherapy assessment) 
Image review : Revised response criteria Data Analysis 
3-4 months after interim 
PET-CT scan 
Patient preparation, FDG injection 
Patient preparation, FDG injection, PET-CT scan post 1 hour FDG injection 
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CHAPTER 4 
 
METHODOLOGY 
 
4.1 Research location 
 Department of Molecular Imaging and Nuclear Medicine, Hospital Canselor 
Tuanku Muhriz (HCTM), Bandar Tun Razak, Cheras, Kuala Lumpur. 
 
4.2 Research design 
This is a prospective cohort study. 
 
4.3 Research period 
The study was conducted from April 2014 to August 2015. 
 
4.4 Sampling 
4.4.1 Target population 
Patients with histopathologically proven lymphoma. 
4.4.2 Population sample 
Lymphoma patients that were subjected to interim FDG PET-CT 
investigations and noted to have MRU lesions following the image review. 
4.4.3 Sample size and dropout rate 
Sample size was calculated using independent t-test. Parameters used are 
estimated from previous study (Itti et al., 2009) with the same population. 
    
 where  Zα = 1.96     Zβ = 0.84 
Δ difference = 3.6  power = 0.8 (80%)    SD, σ = 5      α = 0.05 
